홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /반응

Phthalimide → tert-butyl 4-(1-(4-chlorophenyl)-3-(1,3-dioxoisoindolin-2-yl)propylcarbamoyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-ylcarbamate

HRID 423056
인쇄

반응식

HRID 423056 반응식
C1(P(C2C=CC=CC=2)C2C=CC=CC=2)C=CC=CC=1.[C:20]1(=[O:30])[NH:24][C:23](=[O:25])[C:22]2=[CH:26][CH:27]=[CH:28][CH:29]=[C:21]12.[Cl:31][C:32]1[CH:37]=[CH:36][C:35]([CH:38]([NH:42][C:43]([C:45]2([NH:60][C:61](=[O:67])[O:62][C:63]([CH3:66])([CH3:65])[CH3:64])[CH2:50][CH2:49][N:48]([C:51]3[C:52]4[CH:59]=[CH:58][NH:57][C:53]=4[N:54]=[CH:55][N:56]=3)[CH2:47][CH2:46]2)=[O:44])[CH2:39][CH2:40]O)=[CH:34][CH:33]=1.N(C(OCC)=O)=NC(OCC)=O>C1COCC1>[Cl:31][C:32]1[CH:33]=[CH:34][C:35]([CH:38]([NH:42][C:43]([C:45]2([NH:60][C:61](=[O:67])[O:62][C:63]([CH3:66])([CH3:65])[CH3:64])[CH2:46][CH2:47][N:48]([C:51]3[C:52]4[CH:59]=[CH:58][NH:57][C:53]=4[N:54]=[CH:55][N:56]=3)[CH2:49][CH2:50]2)=[O:44])[CH2:39][CH2:40][N:24]2[C:20](=[O:30])[C:21]3[C:22](=[CH:26][CH:27]=[CH:28][CH:29]=3)[C:23]2=[O:25])=[CH:36][CH:37]=1
참가 물질반응 조건실험 절차후처리출처 및 근거반응 노트

참가 물질

6

반응물 4

HCID 6809PhthalimideHCID 11776TriphenylphosphineHCID 220568ethyl N-ethoxycarbonyliminocarbamateHCID 57750387tert-butyl 4-(1-(4-chlorophenyl)-3-hydroxypropylcarbamoyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-ylcarbamate2회

생성물 1

HCID 57750333
tert-butyl 4-(1-(4-chlorophenyl)-3-(1,3-dioxoisoindolin-2-yl)propylcarbamoyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-ylcarbamate
수율 21.23%

시약·촉매·용매 1

HCID 8028Tetrahydrofuran용매

반응 조건

온도
0 °C

실험 절차

Triphenylphosphine (158 mg) and phthalimide (22.11 mg) were added in one portion to a stirred solution of tert-butyl 4-(1-(4-chlorophenyl)-3-hydroxypropylcarbamoyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-ylcarbamate (Intermediate 36) (53 mg) dissolved in THF (10 mL) and cooled to 0° C. under argon. The resulting solution was stirred at 0° C. for 30 minutes. Diethyl azodicarboxylate (0.093 mL) was added dropwise at 0° C. under argon. The resulting suspension was stirred at 0° C. for 60 minutes and overnight at room temperature. The suspension was quenched with water. The THF was removed in vacuo and the aqueous phase extracted with DCM. The organic phase was dried and concentrated to provide crude product. The crude product was purified by flash chromatography on silica gel eluting with 0 to 10% methanol in DCM. The solvent was evaporated to dryness to afford tert-butyl 4-(1-(4-chlorophenyl)-3-(1,3-dioxoisoindolin-2-yl)propylcarbamoyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-ylcarbamate as a white solid (14.00 mg, 21.23%).

후처리

  1. stirringThe resulting suspension was stirred at 0° C. for 60 minutes and overnight at room temperature
  2. customThe suspension was quenched with water
  3. customThe THF was removed in vacuo
  4. extractionthe aqueous phase extracted with DCM
  5. customThe organic phase was dried
  6. concentrationconcentrated
  7. customto provide crude product
  8. customThe crude product was purified by flash chromatography on silica gel eluting with 0 to 10% methanol in DCM
  9. customThe solvent was evaporated to dryness

출처 및 근거

ORD 기록
ord-1a88c7fb38774fa2a7b7c864b3e52e87
출처 데이터셋
uspto-grants-2012_01
DOI
10.6084/m9.figshare.5104873.v1
특허 번호
US08101623B2

반응 노트

이 페이지에서참가 물질반응 조건실험 절차후처리출처 및 근거반응 노트